Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 4Sarcoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymus Neoplasms 1Sarcoma, Synovial 1Prostatic Neoplasms 1Multiple Myeloma 1Mesothelioma 1Meningioma 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fatigue 1Dermatofibrosarcoma 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Quality of Life × Clear all
NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡